Lupin Pharmaceuticals Partnering with Phil, Inc. for its Patient Access Solution

Phil, Inc. (Phil) was founded to offer pharmaceutical manufacturers an innovative approach to patient access services. Phil’s Patient Access Platform leverages tech to expedite speed-to-therapy while offering an enhanced experience for providers and patients.

Lupin Pharmaceuticals Inc. (Lupin), recently announced a partnership with Phil for patients prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.

Solosec is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. In November 2019, Lupin announced that the FDA accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.

Solosec is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. Solosec is not intended to be dissolved in any liquid.

Lupin is the U.S. based wholly owned subsidiary of Lupin Limited, and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions. Together, all Lupin-owned entities combine to make up the 8th largest generic pharmaceutical company in the world by revenue size. Lupin’s branded pharmaceuticals division provides products designed to help prevent and manage women’s health conditions.

Phil, headquartered in San Francisco, California, is a leading provider of Digital Patient Access Solutions. By addressing patient access challenges using online technologies, as opposed to traditional call-center models, Phil Inc. partners with pharmaceutical manufacturers to deliver pioneering digital access to Specialty and Specialty-Lite therapies.

Phil closed the company’s Series B $25MM funding round in 2019 led by GreatPoint Ventures, with support from Tarsadia Investments, Crosslink Capital and Uncork Capital. The funding was planned to fuel company growth, with a focus on hiring technical talent and expanding geographic footprint. 

Takeaway: Many hub service providers and other companies are developing patient support platforms to improve patient-centric capabilities in order to provide better services that improve patient outcomes